Semaglutide (SEMA) for Alcohol Use Disorder (AUD) After Metabolic and Bariatric Surgery (MBS)

ConditionsAlcohol Use Disorder Weight Loss Bariatric Surgery Patients

Trial statusRecruiting

Trial phasePhase 1

Trial typeInterventional

Biological sexAll

Age18+

SponsorYale University

About this trial

The purpose of this research study is to evaluate the feasibility of treating Alcohol Use Disorder with Semaglutide after metabolic and bariatric surgery in adults with overweight or obesity.

Eligibility criteria

Qualifiers

Provision of signed and dated informed consent form

Stated willingness to comply with all study procedures and availability for the duration of the study (up to 6 months: 3-month treatment plus 3-month follow up)

Age 18 and older

Have a BMI ≥30 (or BMI ≥27 with a medical comorbidity) and BMI ≤50 kg/m2

Disqualifiers

Any of the following: myocardial infarction, stroke, hospitalization for unstable angina, or transient ischemic attack within the past 60 days prior to screening

History or presence of chronic or recurrent pancreatitis

History of malignant neoplasms within the past 5 years prior to screening

Personal or family history of medullary thyroid carcinoma or in patients with Multiple Endocrine Neoplasia syndrome type 2

Trial design

Treatments tested in this trial

Semaglutide 1.0 mg

Treatment groups

10 Participants

are divided into 2 treatment groups

Sponsors and collaborators

Yale University

Lead sponsor

Source ClinicalTrials.gov